Corpus overview


MeSH Disease

Human Phenotype


There are no transmission terms in the subcorpus

    displaying 1 - 4 records in total 4
    records per page

    Effect of COVID-19 on Liver Abnormalities HP Liver Abnormalities MESHD: A Systematic review and Meta‐analysis 

    Authors: Khalid Bzeizi; Maheeba Abdulla; Nafeesa Mohammed; Jehad Alqamish; Negar Jamshidi; Dieter Broering

    doi:10.21203/ Date: 2020-07-20 Source: ResearchSquare

    Emerging evidence suggest association of severe acute r espiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHDwith development of many liver abnormalities HP iver abnormalities. MESHD The overarching aim of this study was therefore to assess the available evidence on the clinical effects of SARS-CoV-2 on liver function laboratory tests and coagulation profile in affected individuals. We considered all study designs including epidemiological and observational that reported liver function test abnormalities in patients diagnosed with S ARS-CoV-2 infection. MESHD Medline, Embase databases and Google Scholar as well as relevant reviews were searched to identify appropriate studies from inception to April 30th, 2020. We calculated pooled mean with 95% confidence intervals (95%CI) through a random-effect model meta-analysis. A total of 29 studies with 9991 participants were considered for the review from which 20 studies with sufficient quantitative data were included for the meta-analysis. The pooled mean for liver enzymes and coagulation parameters did not significantly change in patients affected by COVID-19 and remained within normal range. Our systematic review and meta-analysis findings of the available evidence suggest that COVID-19 did not have a significant impact on the liver enzymes or coagulation profile of patients with S ARS-CoV-2 infection. MESHD Future studies need to adequately report all the liver function parameters with event rates.

    Poor Outcomes in Patients with Cirrhosis HP Cirrhosis MESHD and COVID-19

    Authors: Shalimar; Anshuman Elhence; Manas Vaishnav; Ramesh Kumar; Piyush Pathak; Kapil Dev Soni; Richa Aggarwal; Manish Soneja; Pankaj Jorwal; Arvind Kumar; Puneet Khanna; Akhil Kant Singh; Ashutosh Biswas; Neeraj Nischal; Lalit Dhar; Aashish Choudhary; Krithika Rangarajan; Anant Mohan; Pragyan Acharya; Baibaswata Nayak; Deepak Gunjan; Anoop Saraya; Soumya Mahapatra; Govind Makharia; Anjan Trikha; Pramod Garg

    doi:10.21203/ Date: 2020-07-06 Source: ResearchSquare

    Background and AimThere is a paucity of data on the clinical presentations and outcomes of Coronavirus disease MESHD 2019(COVID-19) in patients with underlying liver disease MESHD. We aimed to summarize the presentations and outcomes of COVID-19 positive patients and compare with historical controls.MethodsPatients with known chronic liver disease MESHD who presented with superimposed COVID- 19(n=28) between 22nd April and 22nd June 2020 were studied. Seventy-eight cirrhotic patients from historical controls were taken as comparison group.ResultsA total of 28 COVID patients- two without cirrhosis HP cirrhosis MESHD, one with compensated cirrhosis HP cirrhosis MESHD, sixteen with acute decompensation (AD), and nine with acute-on-chronic liver failure MESHD( ACLF MESHD) were included. The etiology of cirrhosis HP cirrhosis MESHD was alcohol(n=9), non-alcoholic fatty liver disease MESHD(n=2), viral(n=5), autoimmune hepatitis MESHD hepatitis HP(n=4), and cryptogenic cirrhosis HP(n=6). The clinical presentations included complications of cirrhosis HP cirrhosis MESHD in 12(46.2%), respiratory symptoms in 3(11.5%) and combined complications of cirrhosis HP cirrhosis MESHD and respiratory symptoms in 11(42.3%) patients. The median hospital stay was 8(7-12) days. The mortality rate in COVID-19 patients was 42.3%(11/26), as compared to 23.1%(18/78) in the historical controls(p=0.077). All COVID-19 patients with ACLF(9/9) died compared to 53.3%(16/30) in ACLF of historical controls(p=0.015). Mortality rate was higher in COVID patients with compensated cirrhosis HP cirrhosis MESHD and AD MESHD as compared to historical controls 2/17(11.8%) vs 2/48(4.2%), though not statistically significant (p=0.278). Requirement of mechanical ventilation independently predicted mortality (hazard ratio, 13.68). Both non-cirrhotic patients presented with respiratory symptoms MESHD and recovered uneventfully.ConclusionCOVID-19 is associated with poor outcomes in patients with cirrhosis HP cirrhosis MESHD, with worst survival rates in ACLF. Mechanical ventilation is associated with a poor outcome.

    Liver Function in Novel Coronavirus Disease MESHD (COVID-19): A Systematic Review and Meta-Analysis

    Authors: Mohammad Zahedi; Mohammad Yousefi; Mahdi Abounoori; Mohammad Malekan; Fatemeh Tajik; Keyvan Heydari; Parham Mortazavi; Monireh Ghazaeian; Fateme Sheydaee; Amirreza Nasirzadeh; Reza Alizadeh-Navaei

    doi:10.1101/2020.05.20.20108357 Date: 2020-05-23 Source: medRxiv

    Introduction:The outbreak of new coronavirus has become a global public health challenge. Given a consequential liver function, and the high risk of death MESHD coming from liver disorders MESHD, the assessment of Novel Coronavirus Disease MESHD on liver function is importance. Hence, we carried out this meta-analysis to heightening insight into the occult features of COVID 19, which is likely to affect liver function. Method:This study was performed using databases of Web of Science, Scopus, and PubMed. We considered English cross-sectional and case-series papers, which reported available findings on the association between liver injury MESHD and COVID-19 infection MESHD. We used the STATA v.11 and random effect model for data analysis. Result:In this present meta-analysis, 52 papers, including 8,463 COVID-19 patients, were studied. The prevalence SERO of increased liver enzymes among the patients, including Alanine aminotransferase, Aspartate aminotransferase, were 30% and 21% in non-severe patients, respectively, which were 38% and 48% in severe patients. The prevalence SERO of increasing C-reactive protein, Lactate dehydrogenase, D-dimer, and Bilirubin were 55%, 39%, 28%, and 10% in non-severe patients respectively, which were 78%, 75%, 79% and 17% in sever patients.The prevalence SERO of liver toxicity MESHD as a complication of COVID-19 was 20%.Also patients who have severe condition are 5.54, 4.22, 4.96, 4.13 and 4.34 times more likely to have elevated CRP, ALT, AST, LDH, D-dimer enzymes retrospectively. Conclusion:Elevation of some liver markers were higher in patients with severe COVID-19 infection MESHD. All to gather, we assumed that abnormal liver markers could act as a prognostic factor for a better survey of COVID-19.

    Liver Chemistries in COVID-19 Patients with Survival or Death MESHD: A Meta-Analysis

    Authors: Qing-Qing Xing; Xuan Dong; Yan-Dan Ren; Wei-Ming Chen; Dan-Yi Zeng; Yan-Yan Cai; Mei-Zhu Hong; Jin-Shui Pan

    doi:10.1101/2020.04.26.20080580 Date: 2020-05-01 Source: medRxiv

    Background and Aims: Although abnormal liver chemistries are linked to higher risk of death related to coronavirus disease MESHD (COVID-19), liver manifestations may be diverse and even confused. Thus, we performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19 patients with death MESHD or survival. Methods: We searched PubMed, Google Scholar, medRxiv, bioRxiv, Cochrane Library, Embase, and three Chinese electronic databases through April 22, 2020. We analyzed pooled data on liver chemistries stratified by the main clinical outcome of COVID-19 using a fixed or random-effects model. Results: In the meta-analysis of 18 studies, which included a total of 2,862 patients, the pooled mean alanine aminotransferase (ALT) was 30.9 IU/L in the COVID-19 patients with death MESHD and 26.3 IU/L in the COVID-19 patients discharged alive (p < 0.0001). The pooled mean aspartate aminotransferase (AST) level was 45.3 IU/L in the COVID-19 patients with death MESHD while 30.1 IU/L in the patients discharged alive (p < 0.0001). Compared with the discharged alive cases, the dead cases tended to have lower albumin levels but longer prothrombin time, and international standardized ratio. Conclusions: In this meta-analysis, according to the main clinical outcome of COVID-19, we comprehensively described three patterns of liver impairment MESHD related to COVID-19, hepatocellular injury MESHD, cholestasis HP cholestasis MESHD, and hepatocellular disfunction. Patients died from COVID-19 tend to have different liver chemistries from those are discharged alive. Close monitoring of liver chemistries provides an early warning against COVID-19 related death.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.